| 万新娟,蒋 晨,谢小东,王慧琴,刘晓弟.康柏西普在糖尿病大鼠早期视网膜病变中的作用及对VEGF、ICAM-1及CRP的影响[J].现代生物医学进展英文版,2021,(13):2423-2426. |
| 康柏西普在糖尿病大鼠早期视网膜病变中的作用及对VEGF、ICAM-1及CRP的影响 |
| The Effect of Conbercept in Early Retinopathy of Diabetic Rats and Its Effect on VEGF, ICAM-1 and CRP |
| Received:December 31, 2020 Revised:January 24, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.13.005 |
| 中文关键词: 康柏西普 糖尿病 视网膜病变 血管内皮生长因子 细胞间粘附分子-1 |
| 英文关键词: Conbercept Diabetes Retinopathy Vascular endothelial growth factor Intercellular adhesion molecule-1 |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2017D01C118） |
|
| Hits: 1125 |
| Download times: 545 |
| 中文摘要: |
| 摘要 目的：探讨康柏西普在糖尿病大鼠早期视网膜病变中的作用及对血管内皮生长因子 (vascular endothelial growth factor，VEGF)和细胞间粘附分子-1(Intercellular adhesion molecule-1，ICAM-1)及C-反应蛋白(C-reactive protein，CRP)的影响。方法：糖尿病大鼠早期视网膜病变模型(n=27)随机平分为三组-模型组、替米沙坦组与康柏西普组，造模成功后当天三组分别给予注射生理盐水、替米沙坦、康柏西普治疗，1次/w，持续4 w，检测VEGF、ICAM-1及CRP表达情况。结果：大鼠造模成功后均出现食欲增多、饮水、尿量、体重减轻的现象。替米沙坦组与康柏西普组治疗第1 w与第4 w的体重高于模型组(P<0.05)，康柏西普组高于替米沙坦组(P<0.05)。替米沙坦组与康柏西普组治疗第1 w与第4 w的空腹血糖低于模型组(P<0.05)，康柏西普组低于替米沙坦组(P<0.05)。替米沙坦组与康柏西普组治疗第4 w的视网膜VEGF、ICAM-1、CRP蛋白相对表达水平低于模型组(P<0.05)，康柏西普组低于替米沙坦组(P<0.05)。康柏西普组视网膜厚度变薄不明显，内、外核层细胞排列整齐，神经纤维层未见明显空泡样变性。结论：康柏西普在糖尿病大鼠早期视网膜病变中的应用能抑制VEGF、ICAM-1及CRP的表达，能促进降低血糖，增加大鼠体重。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Conbercept in early retinopathy of diabetic rats and its effects on vascular endothelial growth factor (VEGF) and Intercellular adhesion molecule-1 (ICAM- 1) and C-reactive protein (CRP). Methods: Diabetic rats with early retinopathy model (n=27) were randomly eqaully divided into three groups-model group, telmisartan group and conbercept group. The three groups were given normal saline, telmisartan and conbercept injection on the day after the model were successfully established, once a week for 4 weeks, and the expression of VEGF, ICAM-1 and CRP were detected. Results: All rats were showed increased appetite, drinking water, urine output, and weight loss after successful modeling. The body weight of the telmisartan group and the conbercept group were higher than that of the model group in the 1st week and the 4th week (P<0.05), and the conbercept group were higher than the telmisartan group (P<0.05). The fasting blood glucose of the telmisartan group and the conbercept group were lower than the model group in the 1st and 4th weeks of treatment(P<0.05), and the conbercept group were lower than the telmisartan group(P<0.05). The relative expression levels of retinal VEGF, ICAM-1, and CRP protein in the telmisartan group and the conbercept group were lower than the model group in the 4th week of treatment(P<0.05), and the conbercept group were lower than the telmisartan group(P<0.05). In the compaqcept group, the thickness of the retina were not obvious, the inner and outer nuclear layer cells were arranged neatly, and there were no obvious vacuolar degeneration in the nerve fiber layer. Conclusion: The application of Conbercept in early retinopathy of diabetic rats can inhibit the expression of VEGF, ICAM-1 and CRP, and can promote the reduction of blood sugar and increase the weight of rats. |
|
View Full Text
View/Add Comment Download reader |
| Close |
